Source: Geron Corporation
Date: July 19, 2006
Summary:
Geron Corporation, a leading biotechnology company in the field of stem cell research, has published the results of a study descrbiing its lead human embryonic stem cell (hESC)-based therapeutic product, GRNOPC1, for the treatment of spinal cord injury. Rats that received either very mild or moderate spinal cord injuries were injected with the product. survived in both the mild and moderate lesion sites, with a broader distribution of transplanted cells and robust re-growth of myelin sheath, the coating that insulates nerve cells, in the more severe injuries, replicating previous studies.
No comments:
Post a Comment